GlassScriptPhysician profile
Allison M Boyle
NPI 1992053904
$6,167.88
in general payments reported to CMS, 2019-2025
26 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $851 · 2021: $869 · 2022: $603 · 2023: $1,206 · 2024: $791 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.97 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.79 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Neurocrine Biosciences, INC. | $844.91 | 2019-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $708.84 | 2019-2025 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $663.36 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Merz Pharmaceuticals, LLC | $501.44 | 2021-2025 | Xeomin, Inbrija |
| Acorda Therapeutics, INC | $461.38 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $442.41 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Medtronic USA, INC. | $262.49 | 2019-2020 | |
| Merz North America, INC. | $233.55 | 2019-2020 | |
| Medtronic, INC. | $177.28 | 2023-2025 | Activa PC |
| Kyowa Kirin, INC. | $168.38 | 2019-2024 | Nourianz |
| Ucb, INC. | $111.55 | 2019-2021 | |
| Allergan, INC. | $63.98 | 2020 | |
| Saol Therapeutics INC. | $60.00 | 2020 | |
| Supernus Pharmaceuticals, INC. | $55.46 | 2023-2025 | Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.29 | 2024-2025 | Infinity, Eterna, Proclaim |
| Boston Scientific Corporation | $43.02 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $42.96 | 2020 | |
| Ge Healthcare | $42.26 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $28.25 | 2025 | Dysport |
| Biogen, INC. | $26.17 | 2025 | Skyclarys |
| Avion Pharmaceuticals | $17.31 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.46 | 2019 | |
| Mdd US Operations, LLC | $15.96 | 2020 | |
| Strongbridge US INC. | $14.02 | 2020 | |
| Insightec,INC | $10.36 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.